Alzheimer' Disease, Alzheimer Disease
Conditions
Brief summary
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment arms for 26 weeks administration. The extension study for additional 26 weeks will be conducted open-label with one treatment arm. Subjects will take BEY2153 orally once a day during the study.
Interventions
DRUGBEY2153
Participants administer once daily, PO, 26 weeks
DRUGPlacebo
Participants administer once daily, PO, 26 weeks
Sponsors
BeyondBio Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Male and female adults at the age of ≥ 55 to ≤ 85 at the time of informed consent * Patients diagnosed according to the NIA-AA 2024 Criteria for Diagnosis with Mild Cognitive Impairment (MCI) or diagnosed with mild Alzheimer's disease * CDR-GS 0.5-1.0 at Screening * MMSE ≥ 20 at Screening * Amyloid-positive at amyloid PET scan * Patients who are capable of understanding information provided and can voluntarily sign written informed consent form
Exclusion criteria
* Subjects diagnosed with cognitive impairment due to causes other than substrate causes such as brain lesions, psychiatric disorders, or Alzheimer's disease (e.g., stroke, Parkinson's disease, Lewy body disease, vascular dementia) * Subjects with any of the following cardiovascular diseases at Screening \* Cerebrovascular disease within the past 6 months (cerebral infarction, cerebral hemorrhage, transient ischemic attack, etc.) * Myocardial infarction or unstable angina pectoris within the past 6 months * New York Heart Association (NYHA) Class II congestive heart failure * QTcF ≥450 msec or clinically significant electrocardiogram (ECG) abnormalities * Patients with malignant tumors * Patients with medical conditions that can affect cognitive decline such as hypothyroidism, vitamin B12 or folate deficiency, niacin deficiency, etc. * Patients with a history of alcohol related disorders within the past 6 months * Patients with a positive HIV antibody test result at Screening * Patients with a positive HBs antigen or HCV antibody test at Screening * Patients with active bacterial infections who have received antibiotics within 7 days prior to Screening. * Patients with a history of hypersensitivities to any of the components of investigational product * Patients who have been hospitalized or treated for suicidal behavior within 5 years prior to Screening or whose C-SSRS results at Screening indicate serious suicidal ideation or behavior * Patients who have received treatment for Alzheimer's disease (e.g., Lecanemab) within 6 months prior to Screening * Patients expected to require the administration of a long-acting benzodiazepine (BDZ) for the treatment of sleep disorders at Screening * Any of the following laboratory test values at Screening: * Serum Creatinine \>1.5×ULN or eGFR (MDRD) \<40 mL/min/1.73 m2 * Any of the following: AST, ALT \>3×ULN, or Total bilirubin \>2xULN * Women who test positive for pregnancy at Screening, or women and men of childbearing potential who are planning to become pregnant, or who do not agree to use adequate contraception\* during the study and for 4 weeks after the end of study drug administration \*Adequate contraception: complete abstinence, hormonal contraceptives with no known drug interactions \[Levonorgestrel intrauterine system (IUS) (Mirena), Medroxyprogesterone\], surgical sterilization (including vasectomy, bilateral salpingectomy and ligation). However, intermittent abstinence (e.g., using ovulation timing, symptothermal method, or post-ovulation) or external ejaculation are not considered adequate contraception. * Pregnant or lactating women or women who are tested positive for pregnancy at Screening * Patients treated with other IP within 4 weeks prior to screening * Patients who are considered ineligible for study participation for other reasons based on the judgment of the investigator \[Extension Study\] Inclusion Criteria: * Patients who completed the 26-week visit in the Main Study * Patients who provided written consent to participate in the Extension Study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety: Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | From Baseline until 4 weeks after the end of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in Mini Mental State Exam (MMSE) after 26-week treatment | Baseline and Week 26 |
| Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog 13) after 26-week treatment | Baseline and Week 26 |
| Change from Baseline in Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-Plus) after 26-week treatment | Baseline and Week 26 |
| Change from Baseline in Alzheimer's Disease Composite Score (ADCOMS) after 26-week treatment | Baseline and Week 26 |
| Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) after 26-week treatment | Baseline and Week 26 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Brain imaging: Change in brain atrophy | Baseline and Week 26 | vMRI will be conducted following administration of BEY2153 to evaluate the change in brain atrophy (volume) |
| Brain imaging: Change in brain accumulation of amyloid protein | Baseline and Week 26 | Amyloid PET will be conducted following administration of BEY2153 to evaluate the change in brain accumulation of amyloid protein (centiloid) |
| Pharmacodynamics: Change in concentrations of plasma AD-related biomarkers | Baseline, Week 6 and Week 26 | To assess the effect of BEY2153 on amyloid (Aβ40, Aβ42) and tau (p-tau217, p-tau181, t-tau) related biomarkers in AD patients |
Countries
South Korea
Outcome results
None listed